Everything About Migraine Treatment Options: A Clinical Guide to Acute Relief and Prevention

How Migraine Treatment Is Organized

Triptans, CGRPs, and Botox represent different parts of migraine care rather than interchangeable treatments. Clinical plans generally separate acute or rescue medicines, which are taken during an attack, from preventive therapies, which are used regularly to reduce attack frequency or severity. Additional medicines may address nausea, vomiting, or other symptoms. The University of Utah describes this approach as a treatment toolbox because different therapies serve different purposes and may be combined under medical supervision. 1

Selection depends on attack intensity, associated symptoms, frequency, disability, previous response, medical history, pregnancy status, and potential interactions. Preventive treatment is generally considered when migraine occurs frequently, substantially interferes with work or daily activities, is difficult to control acutely, or contributes to excessive use of rescue medicines. Updated adult guidance recommends considering prevention at four or more migraine days per month or four or more moderate-to-severe headache days per month, as well as when functional impairment is significant. 4

Medicines Used During an Attack

For mild-to-moderate attacks, commonly used acute options include nonsteroidal anti-inflammatory drugs such as ibuprofen, naproxen, diclofenac, or aspirin, along with acetaminophen. Triptans are migraine-specific medicines and are generally more effective than acetaminophen or NSAIDs for many adults with moderate or severe attacks. International Headache Society guidance emphasizes taking acute treatment early in the headache phase, when pain is still mild, because most triptans and NSAIDs do not reliably work during the aura phase. 2

Newer acute options include gepants, which block CGRP pathways, and the ditan lasmiditan. Gepants may be considered when triptans are ineffective, poorly tolerated, or unsuitable because of cardiovascular concerns. Ubrogepant has been reported to work when taken before the headache phase in some circumstances, unlike most conventional acute medicines. Nausea and vomiting can require antiemetics or nonoral formulations, including nasal sprays, injections, suppositories, or orally disintegrating tablets. 3

Preventive Medicines and When They Matter

Preventive medicines are taken on a schedule rather than only at the first sign of pain. Established categories include beta blockers such as propranolol and metoprolol, antiseizure medicines such as topiramate or valproate, and selected antidepressants. The choice involves weighing evidence, side effects, coexisting conditions, reproductive considerations, monitoring requirements, and practical preferences. Traditional options remain relevant because they have longer clinical histories and may be more accessible than newer migraine-specific therapies. 5

Preventive therapy does not necessarily eliminate migraine, and improvement often requires adjustment over time. A personalized plan may change when a medicine causes unwanted effects, fails to reduce migraine days, or does not fit a person’s other health needs. Menstrual patterns can also influence treatment selection. Some people experience attacks around hormonal changes, while hormone-based approaches may be relevant only for selected patients and require individualized assessment because they are not appropriate for every migraine pattern. 6

CGRP Therapies and OnabotulinumtoxinA

CGRP-targeting preventive medicines were developed specifically for migraine prevention. They include monoclonal antibodies administered by injection or infusion and oral gepants such as atogepant and rimegepant. According to reporting on updated prevention guidance, some CGRP medicines reduced migraine frequency by as much as 70 percent in clinical study populations, although individual responses vary and such results do not guarantee the same outcome for every patient. 7

OnabotulinumtoxinA, commonly called Botox in clinical discussions, is an established preventive option for adults with chronic migraine. Chronic migraine is generally defined as headache on at least 15 days per month for more than three months, with migraine features on at least eight days. Treatment involves repeated administration by a trained clinician rather than a single permanent intervention. Decisions must account for diagnosis, treatment response, adverse effects, scheduling, and continued follow-up. 8

Lifestyle, Behavioral, and Device-Based Care

Nonmedication measures complement rather than automatically replace medical treatment. Common elements include consistent sleep, regular meals, hydration, exercise, stress-management techniques, and a headache diary. Tracking headache days, symptoms, menstrual timing, suspected triggers, medication use, and treatment response can help clinicians distinguish patterns and identify possible medication overuse. Trigger management should remain individualized because a factor associated with one person’s attacks may not be relevant to another person. 9

Behavioral and procedural approaches may be useful when medicines are ineffective, poorly tolerated, contraindicated, or insufficient by themselves. Options described in clinical resources include cognitive behavioral therapy, biofeedback, relaxation training, physical therapy, and noninvasive neuromodulation devices. These approaches differ in evidence, availability, training requirements, and suitability. Their role is usually determined by symptom pattern, patient preference, access, and whether the treatment can be integrated into an ongoing prevention and rescue plan. 10

Safety, Medication Overuse, and Clinical Monitoring

Frequent use of acute medicines can produce medication-overuse headache, a cycle in which rescue treatment is associated with increasing headache frequency. The risk is particularly important with triptans, opioids, and combination analgesics, although excessive use of other pain medicines can also be problematic. A clinician may need to establish limits, modify acute treatment, and introduce prevention. Opioids are generally avoided as routine migraine therapy because of dependence, adverse effects, and overuse concerns. 11

Safety assessment is essential before treatment changes. People who are pregnant or breastfeeding, have cardiovascular disease, uncontrolled hypertension, kidney or liver disease, or take interacting medicines may require alternatives, dose adjustments, or specialist input. Sudden severe headache, a new neurological deficit, confusion, fever with concerning symptoms, or a major change from an established pattern warrants urgent medical assessment rather than routine self-treatment. Imaging is not generally required for uncomplicated migraine but may be considered when warning features or atypical findings exist. 12 13 14

Sources

1. University of Utah Health
2. American Family Physician, International Headache Society guideline summary
3. Medscape, International Headache Society pharmacotherapy summary
4. American Academy of Neurology and American Headache Society
5. Science News
6. Healthline
7. National Institute of Neurological Disorders and Stroke
8. NHS
9. Mayo Clinic
10. American Migraine Foundation
11. American Academy of Family Physicians
12. National Institute for Health and Care Excellence
13. Cleveland Clinic
14. American College of Radiology